세계의 만성 폐쇄성 폐질환(COPD) 치료 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2033년)

Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market size is anticipated to grow from USD 27.91 Billion in 2024 to USD 43.37 Billion by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 5.02% during the forecast period of 2026 to 2033.

The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market is poised for significant growth as the prevalence of COPD continues to rise globally. COPD is a progressive lung disease characterized by airflow limitation, leading to breathing difficulties and reduced quality of life. The increasing incidence of risk factors such as smoking, air pollution, and occupational exposures is driving the demand for effective COPD treatments, including bronchodilators, corticosteroids, and combination therapies. As healthcare providers seek to improve patient outcomes and manage symptoms, the market for COPD treatments is expected to flourish.

Technological advancements are playing a crucial role in shaping the future of the COPD treatment market. Innovations in drug delivery systems, such as inhalers and nebulizers, are enhancing the efficacy and convenience of COPD therapies. Additionally, the integration of digital health technologies, including mobile applications and remote monitoring devices, is empowering patients to manage their condition more effectively. As manufacturers continue to invest in research and development, the COPD treatment market is likely to see increased adoption of innovative solutions across various healthcare settings.

Moreover, the growing emphasis on patient education and self-management is influencing the COPD treatment market's growth trajectory. As patients become more informed about their condition and treatment options, there is a rising demand for resources and support systems that facilitate effective self-management. This trend is driving collaboration between healthcare providers, pharmaceutical companies, and patient advocacy groups to develop educational initiatives that empower patients to take control of their health. As the market continues to evolve, the integration of technology, patient engagement, and personalized care will be key drivers of success.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

SEGMENTATION COVERED IN THE REPORT

By Drug Class

• Combination Therapy
• Bronchodilators
• Corticosteroids
• Phosphodiesterase Type 4 Inhibitor
• Mucokinetics
• Others

By Type

• Chronic Bronchitis
• Emphysema

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• COMPANIES PROFILED
• Almirall
• AstraZeneca
• Boehringer Ingelheim International GmbH
• CHIESI Farmaceutici S.p A.
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKiine plc
• Kyowa Hakko Kirin
• Mylan NV.
• Novartis AG
• Orion Corporation
• Sanofi
• Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co. Ltd)
• Teva Pharmaceutical Industries Ltd.
• Theravance Biopharma
• Verona Pharmaceuticals.
• The above list can be customized.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porters Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Drug Class
  • 3.7.2 Market Attractiveness Analysis By Type
  • 3.7.3 Market Attractiveness Analysis By Distribution Channel
  • 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT MARKET ANALYSIS BY DRUG CLASS

• 5.1. Overview By Drug Class
• 5.2. Historical and Forecast Data Analysis By Drug Class
• 5.3. Combination Therapy Historic and Forecast Sales By Regions
• 5.4. Bronchodilators Historic and Forecast Sales By Regions
• 5.5. Corticosteroids Historic and Forecast Sales By Regions
• 5.6. Phosphodiesterase Type 4 Inhibitor Historic and Forecast Sales By Regions
• 5.7. Mucokinetics Historic and Forecast Sales By Regions
• 5.8. Others Historic and Forecast Sales By Regions

6. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT MARKET ANALYSIS BY TYPE

• 6.1. Overview By Type
• 6.2. Historical and Forecast Data Analysis By Type
• 6.3. Chronic Bronchitis Historic and Forecast Sales By Regions
• 6.4. Emphysema Historic and Forecast Sales By Regions

7. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 7.1. Overview By Distribution Channel
• 7.2. Historical and Forecast Data Analysis By Distribution Channel
• 7.3. Hospital Pharmacies Historic and Forecast Sales By Regions
• 7.4. Retail Pharmacies Historic and Forecast Sales By Regions
• 7.5. Online Pharmacies Historic and Forecast Sales By Regions

8. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Regional Outlook
• 8.2. Introduction
• 8.3. North America Sales Analysis
  • 8.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.3.2 North America By Segment Sales Analysis
  • 8.3.3 North America By Country Sales Analysis
  • 8.3.4 United States Sales Analysis
  • 8.3.5 Canada Sales Analysis
  • 8.3.6 Mexico Sales Analysis
• 8.4. Europe Sales Analysis
  • 8.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.4.2 Europe By Segment Sales Analysis
  • 8.4.3 Europe By Country Sales Analysis
  • 8.4.4 United Kingdom Sales Analysis
  • 8.4.5 France Sales Analysis
  • 8.4.6 Germany Sales Analysis
  • 8.4.7 Italy Sales Analysis
  • 8.4.8 Russia Sales Analysis
  • 8.4.9 Rest Of Europe Sales Analysis
• 8.5. Asia Pacific Sales Analysis
  • 8.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.5.2 Asia Pacific By Segment Sales Analysis
  • 8.5.3 Asia Pacific By Country Sales Analysis
  • 8.5.4 China Sales Analysis
  • 8.5.5 India Sales Analysis
  • 8.5.6 Japan Sales Analysis
  • 8.5.7 South Korea Sales Analysis
  • 8.5.8 Australia Sales Analysis
  • 8.5.9 South East Asia Sales Analysis
  • 8.5.10 Rest Of Asia Pacific Sales Analysis
• 8.6. Latin America Sales Analysis
  • 8.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.6.2 Latin America By Segment Sales Analysis
  • 8.6.3 Latin America By Country Sales Analysis
  • 8.6.4 Brazil Sales Analysis
  • 8.6.5 Argentina Sales Analysis
  • 8.6.6 Peru Sales Analysis
  • 8.6.7 Chile Sales Analysis
  • 8.6.8 Rest of Latin America Sales Analysis
• 8.7. Middle East & Africa Sales Analysis
  • 8.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.7.2 Middle East & Africa By Segment Sales Analysis
  • 8.7.3 Middle East & Africa By Country Sales Analysis
  • 8.7.4 Saudi Arabia Sales Analysis
  • 8.7.5 UAE Sales Analysis
  • 8.7.6 Israel Sales Analysis
  • 8.7.7 South Africa Sales Analysis
  • 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT COMPANIES

• 9.1. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Competition
• 9.2. Partnership/Collaboration/Agreement
• 9.3. Merger And Acquisitions
• 9.4. New Product Launch
• 9.5. Other Developments

10. COMPANY PROFILES OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Market Concentration Rate
• 10.3. Almirall
  • 10.3.1 Company Overview
  • 10.3.2 Company Revenue
  • 10.3.3 Products
  • 10.3.4 Recent Developments
• 10.4. AstraZeneca
  • 10.4.1 Company Overview
  • 10.4.2 Company Revenue
  • 10.4.3 Products
  • 10.4.4 Recent Developments
• 10.5. Boehringer Ingelheim International GmbH
  • 10.5.1 Company Overview
  • 10.5.2 Company Revenue
  • 10.5.3 Products
  • 10.5.4 Recent Developments
• 10.6. CHIESI Farmaceutici S.P A.
  • 10.6.1 Company Overview
  • 10.6.2 Company Revenue
  • 10.6.3 Products
  • 10.6.4 Recent Developments
• 10.7. F. Hoffmann-La Roche Ltd.
  • 10.7.1 Company Overview
  • 10.7.2 Company Revenue
  • 10.7.3 Products
  • 10.7.4 Recent Developments
• 10.8. GlaxoSmithKiine Plc
  • 10.8.1 Company Overview
  • 10.8.2 Company Revenue
  • 10.8.3 Products
  • 10.8.4 Recent Developments
• 10.9. Kyowa Hakko Kirin
  • 10.9.1 Company Overview
  • 10.9.2 Company Revenue
  • 10.9.3 Products
  • 10.9.4 Recent Developments
• 10.10. Mylan NV.
  • 10.10.1 Company Overview
  • 10.10.2 Company Revenue
  • 10.10.3 Products
  • 10.10.4 Recent Developments
• 10.11. Novartis AG
  • 10.11.1 Company Overview
  • 10.11.2 Company Revenue
  • 10.11.3 Products
  • 10.11.4 Recent Developments
• 10.12. Orion Corporation
  • 10.12.1 Company Overview
  • 10.12.2 Company Revenue
  • 10.12.3 Products
  • 10.12.4 Recent Developments
• 10.13. Sanofi
  • 10.13.1 Company Overview
  • 10.13.2 Company Revenue
  • 10.13.3 Products
  • 10.13.4 Recent Developments
• 10.14. Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co. Ltd)
  • 10.14.1 Company Overview
  • 10.14.2 Company Revenue
  • 10.14.3 Products
  • 10.14.4 Recent Developments
• 10.15. Teva Pharmaceutical Industries Ltd.
  • 10.15.1 Company Overview
  • 10.15.2 Company Revenue
  • 10.15.3 Products
  • 10.15.4 Recent Developments
• 10.16. Theravance Biopharma
  • 10.16.1 Company Overview
  • 10.16.2 Company Revenue
  • 10.16.3 Products
  • 10.16.4 Recent Developments
• 10.17. Verona Pharmaceuticals
  • 10.17.1 Company Overview
  • 10.17.2 Company Revenue
  • 10.17.3 Products
  • 10.17.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies